-
Neurophet teams up with Eisai Korea on AI-based dementia screening
13 Jan 2026 05:22 GMT
… screening result analysis system.
Eisai Korea will support service … to expand service utilization.
Eisai Korea is the Korean … in neuroscience and oncology. Eisai Korea launched Leqembi (lecanemab), … late November 2024. The drug is indicated for adults …
-
Nuvation Bio and Eisai Enter into Exclusive Licensing Agreement for Taletrectinib in Europe and Additional Countries Outside U.S., China and Japan
12 Jan 2026 17:44 GMT
… with a leading oncology partner Eisai will receive exclusive development, registration … ). DRUG INTERACTIONS Strong and Moderate CYP3A Inhibitors/CYP3A Inducers and Drugs … and X ( @nuvationbioinc ). About Eisai Co., Ltd. Eisai's Corporate Concept …
-
Understanding Alzheimer’s Disease and Its Management
16 Jan 2026 17:37 GMT
… like injector that delivers the drug by subcutaneous injection.18 In … defined and objectively monitored. Psychotropic drugs, including antidepressants, benzodiazepines, and … irmb) product information. Nutley, NJ: Eisai Inc; August 2025.
19. Kisunla …
-
The clinical candidates pharma execs are tracking
16 Jan 2026 14:43 GMT
…
BioNTech is among the drug developers advancing therapies that work … ’s rivals Biogen and Eisai made history a few … approvals for their amyloid-targeting drugs Kisunla and Leqembi, respectively. … expects topline data for the drug, azetukalner, from a phase …
-
Science podcast: cracking the Alzheimer’s code
16 Jan 2026 12:25 GMT
… ) in the US. But the drug's path to patients … firm Biogen and Japanese firm Eisai – and donanemab, sold by Eli … Kisunla.
Experts have hailed these drugs as breakthroughs but the decision … approval of the first new drug for Alzheimer’s disease in …
-
<![CDATA[Dr Raghav on the Rationale for Investigating Telisotuzumab Adizutecan in ctDNA+ CRC]]>
16 Jan 2026 01:05 GMT
… Temab-A], a MET antibody-drug conjugate.”
Kanwal P.S. … of the MET-directed antibody-drug conjugate Temab-A, Raghav … Daiichi Sankyo/Astra Zeneca, Eisai, Merck, and Seagen. He … Daiichi Sankyo/Astra Zeneca, Eisai, Guardant Health, HiberCell, Innovent …
-
Hemophagocytic Lymphohistiocytosis Market Poised for Phenomenal Expansion in the US at a CAGR of 24.5% During the Forecast Period (2025-2034) | DelveInsight
16 Jan 2026 00:25 GMT
… the hemophagocytic lymphohistiocytosis drugs @ Hemophagocytic Lymphohistiocytosis Drugs Market
Recent … the pipeline landscape, pipeline drug profiles, including clinical … Biosciences Co.Ltd, BioSenic, Eisai, Vertex Pharmaceuticals, Kyverna Therapeutics …
-
BMS Names Dr. Harald Hampel SVP, Global Neuroscience Head
15 Jan 2026 23:56 GMT
… Senior Vice President, Neurology, at Eisai. Hampel is also the founding … of Alzheimer’s disease. At Eisai, he supported development, approval, and … in December 2025 to lower drug prices for Americans to the …
-
EU (European Union) and UK Medical Device Regulation (MDR) and the In-Vitro Diagnostic Regulation (IVDR) Update Training Course (Online Event: April 29, 2026) - ResearchAndMarkets.com
15 Jan 2026 22:21 GMT
… :
David Jefferys
Senior Vice President
Eisai
Dr David Jefferys is currently … Senior Vice President with Eisai responsible for Global Regulatory, Government … lectured and published extensively in drug and device regulation and on …
-
<![CDATA[PFS Benefit With Lenvatinib/Everolimus Shows Importance of Prioritizing Efficacy Data in ccRCC Treatment Decision-Making]]>
14 Jan 2026 16:43 GMT
… with Janssen, Intellisphere, AVEO, Exelixis, Eisai, Pfizer, and Tolmar; receiving honoraria … fda.gov/drugs/resources-information-approved-drugs/lenvatinib-combination … fda.gov/drugs/resources-information-approved-drugs/cabozantinib- …
About
© 1995-2026